IP Library Granted Patent US 8,759,539
Granted Patent B2
US 8,759,539 · App. 13/125,088 · Granted Jun 24, 2014

Substituted bicyclic amines for the treatment of diabetes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,539
App. No.
13/125,088
Granted
Jun 24, 2014
Kind
B2
Abstract

Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.

Claims (159)

1. A compound of structural formula I:

or a pharmaceutically acceptable salt thereof; wherein

Ar is an aryl or heteroaryl, wherein the aryl or heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of:

—OC 1-10 alkyl,

—OC 3-6 cycloalkyl,

—O-heteroaryl,

—O-aryl,

aryl,

aryl substituted with one to three halogen,

aryl substituted with one to three C 1-10 alkyl,

heteroaryl,

heteroaryl substituted with one to three halogen,

heteroaryl substituted with one to three C 1-10 alkyl,

halogen,

—CO 2 H,

—C 1-10 alkoxycarbonyl,

—CN,

—CF 3 ,

NH 2

pyrrolidone,

cycloheteroalkyl,

C 1-10 alkyl,

C 3-6 cycloalkyl, and

C 3-6 cycloalkyl substituted with one to three C 1-10 alkyl;

X is O, NH or OCH 2 ;

R 1 is SO 2 H, CONHC 1-10 alkyl, —C 1-10 alkoxycarbonyl, aroyl, heteroaroyl, aryl, heteroaryl, cycloalkyl or cycloheteroalkyl wherein the CONHC 1-10 alkyl, —C 1-10 alkoxycarbonyl, aroyl, heteroaroyl, aryl, heteroaryl, cycloalkyl or cycloheteroalkyl are optionally substituted with one or more substituents independently selected from the group consisting of:

—OH,

—OC 1-10 alkyl,

—OC 3-6 cycloalkyl,

—O heteroaryl,

—O aryl,

aryl substituted with one to three halogen,

aryl,

aryl substituted with one to three C 1-10 alkyl,

heteroaryl,

halogen,

SO 2 C 1-10 alkyl,

SO 2 -aryl,

SO 2 -aryl-C 1-10 alkyl,

—C(O)H,

—C(O)C 1-10 alkyl,

—C(O)C 3-6 cycloalkyl,

—C(O) cycloalkyl,

—C(O) heteroaryl,

—C(O) aryl,

—OC(O)H,

—OC(O)C 1-10 alkyl,

—OC(O)C 3-6 cycloalkyl,

—OC(O) cycloalkyl,

—OC(O) heteroaryl,

—OC(O) aryl,

—NH 2 ,

CONH—C 1-10 alkyl-aryl,

—CONH 2 ,

—CO 2 H,

—C 1-10 alkoxycarbonyl,

—CO 2 C 1-10 alkylaryl,

—CN,

—CF 3 ,

—OCF 3 ,

—OCHF 2 ,

cycloheteroalkyl,

pyrrolidone,

C 1-10 alkyl-OH,

C 1-10 alkyl, and

C 3-6 cycloalkyl.

2. The compound or salt of claim 1 , wherein Ar is phenyl.

3. The compound or salt of claim 1 , wherein Ar is substituted with:

CO 2 H,

—OC 1-10 alkyl,

aryl substituted with one to three halogen,

heteroaryl,

aryl,

aryl substituted with one to three C 1-10 alkyl,

C 1-10 alkyl, and

C 3-6 cycloalkyl.

4. The compound or salt of claim 1 , wherein R 1 is aroyl or heteroaroyl.

5. The compound or salt of claim 1 , wherein R 1 is heteroaryl.

6. The compound or salt of claim 1 , wherein R 1 is substituted with:

—OC 1-10 alkyl,

halogen,

SO 2 C 1-10 alkyl,

—NH 2 ,

—CONH 2 ,

—CO 2 H,

—C 1-10 alkoxycarbonyl,

—CO 2 C 1-10 alkylaryl,

—CF 3 ,

—OCHF 2 ,

C 1-10 alkyl-OH, and

C 1-10 alkyl.

7. The compound or salt of claim 1 , wherein R 1 is selected from the group consisting of:

8. The compound or salt of claim 1 selected from the group consisting of:

9. A composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

10. A method of treating diabetes comprising administering to a patient in need thereof a therapeutic amount of a compound of claim 1 .

11. A compound of structural formula Ia:

or a pharmaceutically acceptable salt thereof; wherein

R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of:

—OH,

—OC 1-10 alkyl,

—OC 3-6 cycloalkyl,

—O heteroaryl,

—O aryl,

aryl substituted with one to three halogen,

heteroaryl,

halogen,

—C(O)H,

—C(O)C 1-10 alkyl,

—C(O)C 3-6 cycloalkyl,

—C(O) cycloalkyl,

—C(O) heteroaryl,

—C(O) aryl,

—OC(O)H,

—OC(O)C 1-10 alkyl,

—OC(O)C 3-6 cycloalkyl,

—OC(O) cycloalkyl,

—OC(O) heteroaryl,

—OC(O) aryl,

—CO 2 H,

—C 1-10 alkoxycarbonyl,

—CN,

—CF 3 ,

—OCF 3 ,

—OCHF 2 ,

cycloheteroalkyl,

C 1-10 alkyl, and

C 3-6 cycloalkyl.

12. A compound of structural formula lb:

or a pharmaceutically acceptable salt thereof; wherein R 6 , R 7 , R 8 and R 9 are independently selected from the group consisting of:

—OH,

—OC 1-10 alkyl,

—OC 3-6 cycloalkyl,

—O heteroaryl,

—O aryl,

aryl substituted with one to three halogen,

heteroaryl,

halogen,

—C(O)H,

—C(O)C 1-10 alkyl,

—C(O)C 3-6 cycloalkyl,

—C(O) cycloalkyl,

—C(O) heteroaryl,

—C(O) aryl,

—OC(O)H,

—OC(O)C 1-10 alkyl,

—OC(O)C 3-6 cycloalkyl,

—OC(O) cycloalkyl,

—OC(O) heteroaryl,

—OC(O) aryl,

—CO 2 H,

—C 1-10 alkoxycarbonyl,

—CN,

—CF 3 ,

—OCF 3 ,

—OCHF 2 ,

cycloheteroalkyl,

C 1-10 alkyl, and

C 3-6 cycloalkyl; and

wherein Y is O, S or N.

Assignments (3)
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2011
From: HE, JIAFANG; BAWIEC, JOHN; LIU, WEIGUO; LIANG, GUI-BAI; YANG, LIHU
To: MERCK SHARP & DOHME CORP
Reel/Frame 026156/0490 →